CurrentCignaPolicy IP0540

Aflibercept Products Coverage Policy

Cigna coverage policy for intravitreal aflibercept products (Eylea, Eylea HD, Pavblu) detailing prior authorization requirements, indication-specific medical necessity criteria, dosing limits, employer/individual plan preferred-product step criteria, exclusions (concomitant VEGF inhibitor use), and HCPCS/J-codes for billing.

Policy Summary

PayerCigna

PolicyAflibercept Products Coverage Policy

Policy CodePolicy IP0540

Change TypeMultiple revisions (additions, coding updates, dosing/criteria clarifications)

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain prior authorization and ensure intravitreal aflibercept is prescribed by or in consultation with an ophthalmologist and that dosing and criteria are documented per policy.

SourceLink

POLICY UPDATE CHANGES

Updated review date, disclaimer, refreshed background, references, and change history; rephrased baseline visual acuity threshold for diabetic macular edema to '20/50 or worse (< 69 ETDRS letters)' and clarified as ETDRS BCVA.

Pavblu (biosimilar to Eylea) was added to the policy; conditions and criteria for Pavblu identical to Eylea.

Updated HCPCS coding: removed J3590 and added J0177 (effective 4/1/2024); later revisions added Q5147 (effective 4/1/2025) and noted temporary codes C9399, J3490, J3590 effective until 3/31/2025.

Conditions Not Covered: 'Concomitant Use with Another Intravitreal Vascular Endothelial Growth Factor Inhibitor' was added as an exclusion.

Eylea HD dosing and indications updated to align with revised prescribing information including recommended regimens and dosing intervals; dosing interval language standardized to 'not more frequent than once every 21 days' for Eylea HD.

6Listed indications for Eylea/Pavblu

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Listed indications for Eylea HD

1Prior authorization required

1Explicit exclusion: concomitant intravitreal VEGF inhibitors

Coverage Summary

This policy (IP0540) is effective 02/01/2026 and was last reviewed on 02/01/2026. It applies to intravitreal aflibercept products (Eylea, Eylea HD, Pavblu) and states a coverage stance of covered with criteria, requiring prior authorization and indication‑specific medical necessity criteria for benefit coverage.

Dosing Interval and DME Visual Acuity Threshold

Eylea / Pavblu dosing interval (most indications)Not more frequent than once every 25 days (2 mg intravitreal injection)

Eylea HD dosing intervalNot more frequent than once every 21 days (8 mg intravitreal injection)

Retinopathy of prematurity (ROP) dosing intervalNot more frequent than once every 10 days (0.4 mg intravitreal injection)

DME baseline visual acuity threshold (ETDRS BCVA)20/50 or worse (< 69 ETDRS letters) — used in preferred-product/step criteria

Background & Evidence

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor administered by intravitreal injection to treat multiple retinal and neovascular eye disorders; intravitreal VEGF inhibitors reduce ocular neovascularization and macular edema. Pavblu is identified as a biosimilar to Eylea with the same mechanism, route, and dosage form. Eylea HD is a higher‑dose aflibercept formulation with distinct dosing regimens and recommended higher per‑injection dose. These agents are used for labeled ophthalmic indications and have also been used off‑label for other neovascular eye conditions.

ETDRS BCVA: Early Treatment Diabetic Retinopathy Study best‑corrected visual acuity (ETDRS BCVA) is referenced in the policy for baseline visual acuity criteria.

Repackaged bevacizumab: Compounded bevacizumab (Avastin) used off‑label as intravitreal injection (repackaged bevacizumab) is defined and used in preferred product step criteria.

Prescribing information references: Eylea PI Oct 2024; Pavblu PI Aug 2024; Eylea HD PI Nov 2025.

Supporting review article: Hang A et al., Pharmaceuticals 2023;16:1140.

Medically Necessary — Eylea and Pavblu (Initial Therapy)

Eylea and Pavblu - Medically Necessary Criteria

Eylea and Pavblu are considered medically necessary when ONE of the following is met:

ANY of the following

ALL of the following
- Medication is administered by, or under the supervision of, an ophthalmologist
- Preferred product criteria is met for the product(s) as listed in the preferred product tables
- Dosing
  - Dose is 2 mg administered by intravitreal injection for each eye being treated

Medically Necessary — Eylea HD (Initial Therapy)

Eylea HD - Medically Necessary Criteria

Eylea HD is considered medically necessary when ONE of the following is met:

ANY of the following

ALL of the following
- Medication is administered by, or under the supervision of, an ophthalmologist
- Preferred product criteria is met for the product(s) as listed in the preferred product tables
- Dosing
  - Dose is 8 mg administered by intravitreal injection for each eye being treated

Preferred Product Step Criteria (Employer / Individual & Family Plans)

Approval Duration & Continuation Criteria

Approvals are typically provided for 1 year for the listed indications. The policy notes that extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Prior authorization is required for coverage and approvals require prescription by or consultation with an appropriate specialist (ophthalmologist).

Conditions Not Covered (Exclusions)

The policy specifies that Eylea, Eylea HD, Pavblu for any other use is considered not medically necessary, including concurrent (concomitant) use with another intravitreal VEGF inhibitor.

Provider Actions & Billing Requirements

Prior Authorization

Prior Authorization required

Prior authorization is required for benefit coverage of intravitreal aflibercept products; approvals are provided for the durations specified (typically 1 year) and extended approvals are allowed if criteria and dosing continue to be met.

Documentation Required

Prescriber specialty and supervision

Medication must be administered by, or under the supervision of, an ophthalmologist; approvals require prescription by or consultation with a physician who specializes in the condition being treated.

Documentation Required

Preferred product step documentation

For employer and individual/ family plans, document prior use of repackaged bevacizumab and demonstration of inadequate efficacy or intolerance when applicable. Alternatively, when invoking exceptions for diabetic macular edema, document baseline ETDRS best-corrected visual acuity (BCVA) of 20/50 or worse (< 69 ETDRS letters) and/or significant retinal thickening per the prescriber as specified in the preferred-product step criteria.

Applicable HCPCS / J-Codes

Considered Medically Necessary HCPCS/J-codesHCPCSCovered

C9399	Unclassified drugs or biologicals (Code effective until 3/31/2025)
J0177	Injection, aflibercept HD, 1 mg (Code effective 4/1/2024)
J0178	Injection, aflibercept, 1 mg
J3490	Unclassified drugs (Code effective until 3/31/2025)
J3590	Unclassified biologics (Code effective until 3/31/2025)
Q5147	Injection, aflibercept-ayyh (Pavblu), biosimilar, 1 mg (Code effective 4/1/2025)

Clinical Evidence & References

Prescribing information references supporting the policy: Eylea PI Oct 2024; Pavblu PI Aug 2024; Eylea HD PI Nov 2025.

Supporting review article: Hang A et al., Pharmaceuticals 2023;16:1140.

Policy Details & Definitions

Scope: Cigna coverage policy for intravitreal aflibercept products (Eylea, Eylea HD, Pavblu) detailing prior authorization requirements, indication‑specific medical necessity criteria, dosing limits, employer/individual plan preferred‑product step criteria, exclusions (including concomitant VEGF inhibitor use), and HCPCS/J‑codes for billing. Status: CURRENT. The policy references ETDRS BCVA and repackaged bevacizumab in scope and definitions used for preferred‑product steps.

Revision History

12/01/2024revised

02/01/2025added

Pavblu (biosimilar to Eylea) was added to the policy; conditions and criteria for Pavblu identical to Eylea.

02/01/2025revised

Policy Summary

PayerCigna

PolicyAflibercept Products Coverage Policy

Policy CodePolicy IP0540

Change TypeMultiple revisions (additions, coding updates, dosing/criteria clarifications)

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain prior authorization and ensure intravitreal aflibercept is prescribed by or in consultation with an ophthalmologist and that dosing and criteria are documented per policy.

SourceLink

On This Page

Dosing interval is not more frequent than once every 25 days for each eye being treated

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 2 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 25 days for each eye being treated

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 2 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 25 days for each eye being treated

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 2 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 25 days for each eye being treated

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 0.4 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 10 days for each eye being treated

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 2 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 25 days for each eye being treated

Dosing interval is not more frequent than once every 21 days for each eye being treated

Recommended regimen: one dose every 4 weeks for first 3 doses, then one dose every 8 to 16 weeks; some patients may benefit from every 4-week dosing

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 8 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 21 days for each eye being treated
- Recommended regimen: one dose every 4 weeks for first 3 doses, then one dose every 8 to 12 weeks; some patients may benefit from every 4-week dosing

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 8 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 21 days for each eye being treated
- Recommended regimen: one dose every 4 weeks for first 3-5 doses, then one dose every 8 weeks; some patients may benefit from every 4-week dosing

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 8 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 21 days for each eye being treated
- Recommended regimen: one dose every 4 weeks for first 3 doses, then one dose every 8 to 16 weeks; some patients may benefit from every 4-week dosing

ALL of the following

Medication is administered by, or under the supervision of, an ophthalmologist
Preferred product criteria is met for the product(s) as listed in the preferred product tables
Dosing
- Dose is 8 mg administered by intravitreal injection for each eye being treated
- Dosing interval is not more frequent than once every 21 days for each eye being treated

Denial Risk

Dose and interval limits enforcement

Claims may be denied if dosing exceeds specified amounts per injection or if dosing intervals are more frequent than permitted. The policy enforces interval limits: Eylea and Pavblu — not more frequent than once every 25 days for most indications (2 mg dose); Eylea HD — not more frequent than once every 21 days (8 mg dose); Retinopathy of prematurity — not more frequent than once every 10 days (0.4 mg dose).

Billing Rule

Use appropriate HCPCS/J-codes

Providers must bill using the appropriate HCPCS/J-codes listed in the policy. Considered medically necessary codes include: C9399; J0177; J0178; J3490; J3590; Q5147. Deleted codes and codes not effective at the time of service may be ineligible for reimbursement.

C9399
J0177
J0178
J3490
J3590
Q5147

Updated HCPCS coding: removed J3590 and added J0177 (effective 4/1/2024); later revisions added Q5147 (effective 4/1/2025) and noted temporary codes C9399, J3490, J3590 effective until 3/31/2025.

03/15/2025revised

Updated HCPCS coding: removed J3590 and added J0177 (effective 4/1/2024); later revisions added Q5147 (effective 4/1/2025) and noted temporary codes C9399, J3490, J3590 effective until 3/31/2025.

09/15/2025added

Conditions Not Covered: 'Concomitant Use with Another Intravitreal Vascular Endothelial Growth Factor Inhibitor' was added as an exclusion.

02/01/2026addedLatest

Conditions Not Covered: 'Concomitant Use with Another Intravitreal Vascular Endothelial Growth Factor Inhibitor' was added as an exclusion.

02/01/2026revisedLatest

Eylea HD dosing and indications updated to align with revised prescribing information including recommended regimens and dosing intervals.

02/01/2026revisedLatest

Annual Revision 02/01/2026; dosing interval language standardized to 'not more frequent than once every 21 days' for Eylea HD.